Abstract
The idea of CAR-T cell therapy emerged in the early 1990s, as scientists discovered the application of CD3ζ in its effectiveness of activating T cells. Through generations of improvements by implementing costimulatory domains, the therapy demonstrated an excellent prognosis in refractory DLBCL patients. This paper is going to address the mechanism and basic structures of CAR-T therapy. In addition, this paper will analyze the result of several clinical trials and compare the efficacy of the therapy to the current second-line treatments while pointing out its limitations and efficacy in DLBCL. It is the hope that this paper can give an overview of the therapy while suggesting a superior treatment in DLBCL patients and address some current applications of CAR-T therapy in DLBCL patients while suggesting some future improvements and applications in CAR-T cell therapy. Although Car-T cell therapy showed prominent results over stem cell transplantation in elder patients, its efficacy still required further examinations in order to replace auto-HCT as the second-line treatment of DLBCL.
Publisher
Darcy & Roy Press Co. Ltd.
Reference10 articles.
1. Subklewe, Marion et al. “Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.” Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 46,1 (2019): 15 - 24.
2. “Zhang, C., Liu, J., Zhong, J.F. et al. Engineering CAR-T cells. Biomark Res 5, 22 (2017).
3. Ahmad, Zuhaida, and Wan Yong Ho."ScFv Antibody: Principles and Clinical. Application." Journal of Immunology Research, 15 Mar. 2012.
4. Neelapu, Sattva S et al. “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.” The New England journal of medicine vol. 377, 26 (2017): 2531 - 2544.
5. Schuster, Stephen J et al. “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” The New England journal of medicine vol. 380,1 (2019): 45 - 56.